Zerbe R L
Lilly Research Centre Limited, Surrey, England.
Int J Obes. 1987;11 Suppl 3:191-9.
Observations related to the safety of fluoxetine in the treatment of obese patients are reviewed. The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated. Other than rash, no potentially serious adverse events believed to be related to fluoxetine were observed. Special evaluations of pharmacokinetics, psychomotor impairment, cardiac effects, phospholipidosis and addiction potential have identified no major problems in these areas. It is concluded that fluoxetine use for the treatment of obesity should carry with it minimal risk.
本文综述了有关氟西汀治疗肥胖患者安全性的观察结果。肥胖患者的不良事件情况虽与抑郁症患者略有不同，但相似之处在于观察到的事件通常较为轻微且耐受性良好。除皮疹外，未观察到其他被认为与氟西汀相关的潜在严重不良事件。对药代动力学、精神运动功能损害、心脏效应、磷脂沉积症和成瘾潜力的专项评估未发现这些方面存在重大问题。结论是，使用氟西汀治疗肥胖症的风险应极小。
